KCM
CABA icon

Kynam Capital Management’s Cabaletta Bio CABA Stock Holding History

Kynam Capital Management’s Portfolio CABA Stock Details CABA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-165,486
Closed -$1.53M – 37
2022
Q4 		$1.53M Sell
165,486
-362,319
-69% -$1.32M 0.23% 27
2022
Q3 		$343K Sell
527,805
-18,995
-3% -$22.9K 0.07% 32
2022
Q2 		$580K Sell
546,800
-69,325
-11% -$98K 0.15% 31
2022
Q1 		$1.25M Sell
616,125
-28,458
-4% -$74.4K 0.41% 26
2021
Q4 		$2.44M Buy
+644,583
New +$6.88M 1.31% 22

Other funds holding CABA

FAM
Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Kynam Capital Management's CABA Position: Q1 2023 in Review

Kynam Capital Management sold out of Cabaletta Bio (CABA) in Q1 2023, closing a stake of 165,486 shares — an estimated $1.53M sold.

Kynam Capital Management first reported a position in CABA in Q4 2021 and held it in 5 quarters. The position peaked at $2.44M in Q4 2021. 71 funds tracked by Wall St. Rank hold CABA as of Q1 2023.

  • Kynam Capital Management reported no remaining Cabaletta Bio position as of Q1 2023 after selling out during the quarter.
  • Kynam Capital Management sold 165,486 Cabaletta Bio shares in Q1 2023, an estimated $1.53M.
  • Kynam Capital Management first reported a position in Cabaletta Bio in Q4 2021 and held it in 5 quarters.
  • Kynam Capital Management's Cabaletta Bio position peaked at $2.44M in Q4 2021.
  • 71 funds tracked by Wall St. Rank held Cabaletta Bio as of Q1 2023.

Based on Kynam Capital Management's 13F filing for Q1 2023, filed 15 May 2023.